AbCellera Biologics (ABCL) Change in Receivables (2020 - 2026)

AbCellera Biologics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

• Quarterly Change in Receivables fell 1256.49% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.4 million (down 28.24% YoY) and the FY2025 annual result came in at $55.6 million, down 25.95% from the prior year.
• Change in Receivables was -$13.1 million for Q1 2026 at AbCellera Biologics, down from $39.7 million in the prior quarter.
• Across five years, Change in Receivables topped out at $39.7 million in Q4 2025 and bottomed at -$13.1 million in Q1 2026.
• A 5-year average of $11.0 million and a median of $11.2 million in 2023 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables jumped 1900.0% — and 2026, when it plunged 1256.49%.
• AbCellera Biologics' Change in Receivables stood at $19.0 million in 2022, then plunged by 45.18% to $10.4 million in 2023, then jumped by 99.86% to $20.9 million in 2024, then surged by 90.14% to $39.7 million in 2025, then plunged by 133.03% to -$13.1 million in 2026.
• Business Quant data shows ABCL's Change in Receivables at -$13.1 million in Q1 2026, $39.7 million in Q4 2025, and $3.4 million in Q3 2025.